Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model

Medicin og biovidenskab

• Breast Neoplasms 40%
• Clinical Trials 4%
• Collagen 5%
• Growth 3%
• Lung 3%
• Matrix Metalloproteinase 2 7%
• Matrix Metalloproteinase Inhibitors 75%
• Matrix Metalloproteinases 20%
• Metalloproteases 14%
• Molecular Weight 5%
• N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 100%
• Neoplasm Metastasis 38%
• Neoplasms 15%
• Placebos 14%
• Therapeutics 3%
• Transgenic Mice 6%
• Tumor Burden 6%